Results · Apr-Jun 2026 · filed 5 Aug 2026
Biocon Q1 FY27 results
Sales grew 10% to ₹4,336 crore from ₹3,942 crore in Apr-Jun 2025.
Operating profit grew 13% to ₹847 crore, an operating margin of 19.5% (up 0.5 points from a year ago).
Net profit grew 53% to ₹137 crore from ₹89.2 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −4%, net profit −31%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 4,336 | 3,942 | +10% |
| Operating profit (EBITDA) | 847.2 | 748.9 | +13% |
| Operating margin | 19.5% | 19.0% | +0.5 pts |
| Net profit | 136.8 | 89.2 | +53% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The earnings call
Biocon delivered 10% operating revenue growth in Apr–Jun 2026 with biosimilars growing 17%, driven by recent launches including aflibercept. Management expects meaningful acceleration in the second half as new products ramp & focuses on profitable growth over market share.
The last 7 quarters
Filings that week
- 11 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- 11 Aug 2026Announcement under Regulation 30 (LODR)-Earnings Call Transcript
- 8 Aug 2026Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
- 7 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- 7 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 6 Aug 2026Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors
- 6 Aug 2026Announcement under Regulation 30 (LODR)-Change in Directorate
- 6 Aug 2026Completion Of Tenure Of Statutory Auditors
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.